Tsige Abate Wondesen, Simegn Kalkidan, Beyene Dessale Abate, Ayenew Kassahun Dires, Wondmkun Yehualashet Teshome, Endalifer Bedilu Linger, Ambaye Abyou Seyfu, Dagnew Samuel Berihun, Ayele Siraye Genzeb
Department of Pharmacy, Clinical Pharmacy Unit, Asrat Weldeyes Health Sciences Campus, Debre Berhan University, P.O. Box 445, Debre Berhan, Ethiopia.
Department of Pharmacy, Pharmacology and Toxicology Unit, Asrat Weldeyes Health Sciences Campus, Debre Berhan University, Debre Berhan, Ethiopia.
Sci Rep. 2024 Dec 28;14(1):30804. doi: 10.1038/s41598-024-81425-8.
Rational use of steroids is essential in the long term for improving patient safety. Systemic steroids are important in clinical treatment, but if they are misused, they might have negative effects. This study assessed systemic steroid use and its determinants at Debre Berhan University Hakim Gizawu Teaching Hospital (DBUHGTH), Ethiopia. A cross-sectional study was conducted among 210 admitted patients at the Medical ward of DBUHGTH. A simple random sampling method was used to recruit study participants. The data was collected from patient medical records and patient interviews using a structured data abstraction and patient interview format. Binary logistic regression was employed to identify the potential predictors of systemic steroid use. Finally, the results were interpreted and presented by tables, charts, and graphs. Most study participants were 142 (67.62%) male. The mean age of the participants was 44.94 (SD, 19.2) years. Prednisolone was mostly utilized drug 130 (42.07%), followed by hydrocortisone 81 (26.21%), beclomethasone 58 (18.77%), and dexamethasone 40 (12.94%). Respiratory disorders 112 (53.34%), meningitis 25 (11.91%), and rheumatoid arthritis 19 (9.05%) were the top three disease conditions in which steroids were used with the highest frequency. Most systemic steroids were administered orally, 130 (42.07%). Short-acting (hydrocortisone, beclomethasone) 139 (44.98%) were mostly used, followed by intermediate-acting steroids (prednisolone) 130 (42.07%). Study participants in the 18-40 age range were approximately 2.5 times more likely than those in the 65 + age group to be using systemic steroids (AOR = 2.5, 95% CI 2.86-6.07). Prednisolone was mostly utilized, followed by hydrocortisone, beclometasone, and dexamethasone drugs in the medical ward of DBUHGTH.
从长期来看，合理使用类固醇对于提高患者安全性至关重要。全身性类固醇在临床治疗中很重要，但如果滥用可能会产生负面影响。本研究评估了埃塞俄比亚德布雷伯汉大学哈基姆·吉扎武教学医院（DBUHGTH）全身性类固醇的使用情况及其决定因素。在DBUHGTH内科病房的210名住院患者中进行了一项横断面研究。采用简单随机抽样方法招募研究参与者。通过结构化数据提取和患者访谈的方式从患者病历和患者访谈中收集数据。采用二元逻辑回归来确定全身性类固醇使用的潜在预测因素。最后，通过表格、图表和图形对结果进行解释和呈现。大多数研究参与者为142名男性（67.62%）。参与者的平均年龄为44.94岁（标准差为19.2岁）。泼尼松龙是使用最多的药物，有130例（42.07%），其次是氢化可的松81例（26.21%）、倍氯米松58例（18.77%）和地塞米松40例（12.94%）。呼吸系统疾病112例（53.34%）、脑膜炎25例（11.91%）和类风湿性关节炎19例（9.05%）是类固醇使用频率最高的前三种疾病情况。大多数全身性类固醇通过口服给药，有130例（42.07%）。短效（氢化可的松、倍氯米松）类固醇使用最多，有139例（44.98%），其次是中效类固醇（泼尼松龙）130例（42.07%）。18至40岁年龄组的研究参与者使用全身性类固醇的可能性大约是65岁及以上年龄组参与者的2.5倍（调整后比值比=2.5，95%置信区间2.86 - 6.07）。在DBUHGTH内科病房，泼尼松龙使用最多，其次是氢化可的松、倍氯米松和地塞米松药物。
